RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo...
From Patient to Storyteller: Dale Returns to Shanghai After CAR-T Recovery, Sharing a Journey of Hope
SHANGHAI, Aug. 5, 2026 /PRNewswire/ -- After overcoming stage 4B lymphoma through CAR-T therapy, New Zealand patient Dale has returned to Shanghai—not as a patient seeking treatment, but as a survivor sharing his story. Recently, Dale came back to...
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
CRANBURY, N.J. and SUZHOU,China, Aug. 5, 2026 /PRNewswire/ -- Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA)....
NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- NueCell Bio, a newly established cell therapy science and development services company that utilizes proprietary modular translational development solutions focused on advancing modern cell therapies from...
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026...
Shanghai SinoUnited Hospital Announced Availability of World's First CAR-T Therapy for Solid Tumors in Advanced Gastric Cancer
SHANGHAI, July 3, 2026 /PRNewswire/ -- Shanghai SinoUnited Hospital today announced the availability of satricabtagene autoleucel ("satri-cel"), the world's first chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of solid...
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. The prize, whose laureates from previous cycles have...
From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma
SHANGHAI, May 25, 2026 /PRNewswire/ -- A 36-year-old Pakistani patient has achieved encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui International Cancer Center in Shanghai, following exhausting standard...
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG"...
SinoUnited Health Attracts International Patients as China Emerges as Global Medical Tourism Destination
SHANGHAI, April 14, 2026 /PRNewswire/ -- From CAR-T Cell Therapy and cardiac interventions to health checkups and dental care, China's medical capabilities have increasingly drawn international patients in recent years—underscoring the country's...